Zymeworks reports more Phase I data for ZW25 in HER2-expressing cancers

Zymeworks Inc. (NYSE:ZYME; TSX:ZYME) reported data from 33 evaluable patients with heavily pretreated HER2-expressing cancers in a Phase I trial

Read the full 202 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE